For instance, in tumors with pathogenic BRCA1 mutations associated with hormone receptor positivity, hormone therapy (tamoxifen and aromatase inhibitors) delays tumor progression, reduces risk significantly, and prevents the onset of contralateral tumors [46,47]. This evidence concerns the gene BRCA1 and neoplasm.